Mandate

Vinge advises Expedition Growth Capital in connection with Storykit’s USD 10 million investment round

Vinge advises Expedition Growth Capital in connection with Storykit’s investment round of USD 10 million led by Expedition Growth Capital. The investment in Storykit is Expedition Growth Capital’s first investment in the Nordics.

Serving large and medium sized enterprises, Storykit is leveraging artificial intelligence enabling its users to create video and tell stories on social platforms, and has quickly grown to become the leading video creator in the Nordics as well as recently expanded into several European markets. With the new funding, they will accelerate innovation and expansion at an even higher pace.

Expedition Growth Capital is a USD 200+ million London-based growth equity fund, focused solely on investing in fast growing and capital efficient B2B software companies in Europe and Israel, and this is Expedition Growth Capital’s first investment in the Nordics.

Vinge’s team consisted of Karl Klackenberg, Johan Larsson, Milad Kamali and Nina Gransäter (M&A), Stojan Arnerstål (IPR), Lisa Hörnqvist (Commercial Agreements) and Veronika Garemark (Employment).

 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024